Compare RVP & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RVP | AKTX |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9M | 18.2M |
| IPO Year | 2000 | 2014 |
| Metric | RVP | AKTX |
|---|---|---|
| Price | $0.69 | $7.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $33.50 |
| AVG Volume (30 Days) | 11.8K | ★ 28.4K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $38,266,211.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.78 | N/A |
| 52 Week Low | $0.60 | $0.12 |
| 52 Week High | $1.14 | $29.32 |
| Indicator | RVP | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 41.06 |
| Support Level | $0.66 | $0.21 |
| Resistance Level | $0.74 | $15.50 |
| Average True Range (ATR) | 0.01 | 0.67 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 85.47 | 44.00 |
Retractable Technologies Inc is engaged in the manufacturing and marketing of safety medical products (predominantly syringes) for the healthcare industry. It has manufacturing facilities in Little Elm, Texas, and uses manufacturers in China as well. Its syringes are well-suited for administering vaccinations. The company's products are VanishPoint Syringe, VanishPoint Insulin Syringes, EasyPoint Needle, EasyPoint Blood Collection Tube with Needle, VanishPoint Blood Collection Set, and VanishPoint IV Catheter. It provides solutions such as Insulin, Immunization, Blood Collection, Allergy, General Purpose, and Infusion.
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.